KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes

Molecular Oncology

Volumn 10, Issue 7, 2016, Pages 993-1007

  Sidiropoulos, Konstantinos G ^a,b   Ding, Qiang ^a   Pampalakis, Georgios ^c   White, Nicole M A ^a,b   Boulos, Peter ^a   Sotiropoulou, Georgia ^c   Yousef, George M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Breast cancer subtypes; Kallikrein related peptidase 6 (KLK6); Long term survival outcome score; miR 34a; miRNAs; Pathway analysis

Indexed keywords

COMPLEMENTARY DNA; KALLIKREIN 6; MICRORNA; MICRORNA 146A; MICRORNA 34A; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; SERINE PROTEINASE; 3' UNTRANSLATED REGION; KALLIKREIN; KLK6 PROTEIN, HUMAN;

ARTICLE; BIOGENESIS; BIOINFORMATICS; BREAST CANCER; CELL CYCLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MDA MB 231 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; 3' UNTRANSLATED REGION; BINDING SITE; BIOLOGICAL MODEL; BREAST TUMOR; CASE CONTROL STUDY; CLASSIFICATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; REPRODUCIBILITY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BINDING SITES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; KALLIKREINS; MICRORNAS; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSFECTION;

EID: 84963624387     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.03.008     Document Type: Article

References (61)

1. Anisowicz, A., Sotiropoulou, G., Stenman, G., Mok, S.C., Sager, R., A novel protease homolog differentially expressed in breast and ovarian cancer. Mol. Med. 2 (1996), 624–636.
2. Bayés, A., Tsetsenis, T., Ventura, S., Vendrell, J., Aviles, F.X., Sotiropoulou, G., Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol. Chem. 385 (2004), 517–524.
3. Bhaumik, D., Scott, G.K., Schokrpur, S., Patil, C.K., Campisi, J., Benz, C.C., Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27 (2008), 5643–5647.
4. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70.
5. Chow, T.F., Crow, M., Earle, T., El-Said, H., Diamandis, E.P., Yousef, G.M., Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol. Chem. 389 (2008), 731–738.
6. Creighton, C.J., The molecular profile of luminal B breast cancer. Biologics 6 (2012), 289–297.
7. Diamandis, E.P., Yousef, G.M., Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem. 48 (2002), 1198–1205.
8. Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., Schwarzenback, H., Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin. Chem. 59 (2013), 1489–1496.
9. Engstrom, M.J., Opdahl, S., Hagen, A.I., Romundstad, P.R., Akslen, L.A., Haugen, O.A., Vatten, L.J., Bofin, A.M., Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res. Treat. 140 (2013), 463–473.
10. Ghosh, M.C., Grass, L., Soosaipillai, A., Sotiropoulou, G., Diamandis, E.P., Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol. 25 (2004), 193–199.
11. Hahn, S., Jackstadt, R., Siemens, H., Hunten, S., Hermeking, H., SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. EMBO J. 32 (2013), 3079–3095.
12. Hermeking, H., MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat. Rev. Cancer 12 (2012), 613–626.
13. Huber, M.A., Beug, H., Wirth, T., Epithelial-mesenchymal transition: NF-kappaB takes center stage. Cell Cycle 3 (2004), 1477–1480.
14. Ilic, D., Almeida, E.A., Schlaepfer, D.D., Dazin, P., Aizawa, S., Damsky, C.H., Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J. Cell. Biol. 143 (1998), 547–560.
15. Javeri, A., Ghaffarpour, M., Taha, M.F., Houshmand, M., Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Med. Oncol., 30, 2013, 413.
16. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90.
17. Li, J., Wang, K., Chen, X., Meng, H., Song, M., Wang, Y., Xu, X., Bai, Y., Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol. Biol., 13, 2012, 4.
18. Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Korner, H., Knyazev, P., Diebold, J., Hermeking, H., Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7 (2008), 2591–2600.
19. Luo, D., Wilson, J.M., Harvel, N., Liu, J., Pei, L., Huang, S., Hawthorn, L., Shi, H., A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J. Transl. Med., 11, 2013, 57.
20. Mulrane, L., McGee, S.F., Gallagher, W.M., O'Connor, D.P., miRNA dysregulation in breast cancer. Cancer Res. 73 (2013), 6554–6562.
21. Nagahara, H., Mimori, K., Utsunomiya, T., Barnard, G.F., Ohira, M., Hirakawa, K., Mori, M., Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin. Cancer Res. 11 (2005), 6800–6806.
22. Nakshatri, H., Bhat-Nakshari, P., Martin, D.A., Goulet, R.J. Jr., Sledge, G.W. Jr., Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17 (1997), 3629–3639.
23. Nathalie, H.V., Chris, P., Serge, G., Catherine, C., Benjamin, B., Claire, B., Christelle, P., Briollais, L., Pascale, R., Marie-Lise, J., Yves, C., High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis. J. Cell. Mol. Med. 13 (2009), 4014–4022.
24. Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, N., Coppe, J.P., Tong, F., Speed, T., Spellman, P.T., DeVries, S., Lapuk, A., Wang, N.J., Kuo, W.L., Stilwell, J.L., Pinkel, D., Albertson, D.G., Waldman, F.M., McCormick, F., Dickson, R.B., Johnson, M.D., Lippman, M., Ethier, S., Gazdar, A., Gray, J.W., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 (2006), 515–527.
25. Ni, X., Zhang, W., Huang, K.C., Wang, Y., Ng, S.K., Mok, S.C., Berkowitz, R.S., Ng, S.W., Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br. J. Cancer 91 (2004), 725–731.
26. Nugent, M., Miller, N., Kerin, M.J., Circulating miR-34a levels are reduced in colorectal cancer. J. Surg. Oncol. 106 (2012), 947–952.
27. Ogawa, K., Utsunomiya, T., Mimori, K., Tanaka, F., Inoue, H., Nagahara, H., Murayama, S., Mori, M., Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin. Cancer Res. 11 (2005), 2889–2893.
28. Pampalakis, G., Sotiropoulou, G., Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol. Chem. 387 (2006), 773–782.
29. Pampalakis, G., Prosnikli, E., Agalioti, T., Vlahou, A., Zoumpourlis, V., Sotiropoulou, G., A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res. 69 (2009), 3779–3787.
30. Papadopoulos, G.L., Alexiou, P., Maragkakis, M., Reczko, M., Hatzigeorgious, A.G., DIANA-mirPath: integrating human and mouse microRNAs in pathways. Bioinformatics 25 (2009), 1991–1993.
31. Pasic, M.D., Samaan, S., Yousef, G.M., Genomic medicine: new frontiers and new challenges. Clin. Chem. 59 (2013), 158–167.
32. Pasic, M.D., Olkhov, E., Bapat, B., Yousef, G.M., Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there. Biol. Chem. 393 (2012), 319–330.
33. Peter, M.E., Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 29 (2010), 2161–2164.
34. Petraki, C., Dubinski, W., Scorilas, A., Saleh, C., Pasic, M.D., Komborozos, V., Khalil, B., Gabril, M.Y., Streutker, C., Diamandis, E.P., Yousef, G.M., Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. Pathol. Res. Pract. 208 (2012), 104–108.
35. Peurala, H., Greco, D., Heikkinen, T., Kaur, S., Bartkova, J., Jamshidi, M., Aittomaki, K., Heikkila, P., Bartek, J., Blomqvist, C., Butzow, R., Nevanlinna, H., MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS One, 6, 2011, e26122.
36. Qin, W., Zhang, K., Kliethermes, B., Ruhlen, R.L., Browne, E.P., Arcaro, K.F., Sauter, E.R., Differential expression of cancer associated proteins in breast milk based on age at first full term pregnancy. BMC Cancer, 12, 2012, 100.
37. Reis-Filho, J.S., Pusztai, L., Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378 (2011), 1812–1823.
38. Seiz, L., Dorn, J., Kotzsch, M., Walch, A., Grebenchtchikov, N.I., Gkazepis, A., Schmalfeldt, B., Kiechle, M., Bayani, J., Diamandis, E.P., Langer, R., Sweep, F.C., Schmitt, M., Magdolen, V., Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol. Chem. 393 (2012), 391–401.
39. Sidiropoulos, K.G., White, N.M., Bui, A., Ding, Q., Boulos, P., Pampalakis, G., Khella, H., Samuel, J.N., Sotiropoulou, G., Yousef, G.M., Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. Oncoscience 1 (2014), 709–724.
40. Siemens, H., Jackstadt, R., Hunten, S., Kaller, M., Menssen, A., Gotz, U., Hermeking, H., miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10 (2011), 4256–4271.
41. Sinha, A.U., Kaimal, V., Chen, J., Jegga, A.G., Dissecting microregulation of a master regulatory network. BMC Genomics, 9, 2008, 88.
42. Smalley, M.J., Reis-Filho, J.S., Ashworth, A., BRCA2 and stem cells: tumour typecasting. Nat. Cell Biol. 10 (2008), 377–379.
43. Sotiropoulou, G., Rogakos, V., Tsetsenis, T., Pampalakis, G., Zafiropoulos, N., Simillides, G., Yiotakis, A., Diamandis, E.P., Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol. Rep. 13 (2003), 381–391.
44. Sotiropoulou, G., Pampalakis, G., Diamandis, E.P., Functional roles of human kallikrein-related peptidases. J. Biol. Chem. 284 (2009), 32989–32994.
45. Sotiropoulou, G., Pampalakis, G., Lianidou, E., Mourelatos, Z., Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15 (2009), 1443–1461.
46. Sotiropoulou, G., Pampalakis, G., Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol. Sci. 33 (2012), 623–634.
47. Trimis, G., Chatzistamou, I., Politi, K., Kiaris, H., Papavassiliou, A.G., Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Hum. Mol. Genet. 17 (2008), 3596–3600.
48. Voduc, K.D., Cheang, M.C., Tyldesley, S., Gelmon, K., Nielsen, T.O., Kennecke, H., Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28 (2010), 1684–1691.
49. Vogt, M., Munding, J., Gruner, M., Liffers, S.T., Verdoodt, B., Hauk, J., Steinstrasser, L., Tannapfel, A., Hermeking, H., Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 458 (2011), 313–322.
50. Wang, S.M., Mao, J., Li, B., Wu, W., Tang, L.L., [Expression of KLK6 protein and mRNA in primary breast cancer and its clinical significance]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 24 (2008), 1087–1089.
51. Wang, F., Zheng, Z., Guo, J., Ding, X., Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 119 (2010), 586–593.
52. White, N.M., Bui, A., Mejia-Guerrero, S., Chao, J., Soosaipillai, A., Youssef, Y., Mankaruos, M., Honey, R.J., Stewart, R., Pace, K.T., Sugar, L., Diamandis, E.P., Dore, J., Yousef, G.M., Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol. Chem. 391 (2010), 411–423.
53. White, N.M., Chow, T.F., Mejia-Guerrero, S., Diamandis, M., Rofael, Y., Faragalla, H., Mankaruous, M., Gabril, M., Girgis, A., Yousef, G.M., Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br. J. Cancer 102 (2010), 1244–1253.
54. White, N.M., Youssef, Y.M., Fendler, A., Stephan, C., Jung, K., Yousef, G.M., The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biol. Chem. 393 (2012), 379–389.
55. Yousef, G.M., Obiezu, C.V., Luo, L.Y., Magklara, A., Borgono, C.A., Kishi, T., Memari, N., Michael, I.P., Sidiropoulos, M., Kurlender, L., Economopoulou, K., Kapadia, C., Komatsu, N., Petraki, C., Elliott, M., Scorilas, A., Katsaros, D., Levesque, M.A., Diamandis, E.P., Human tissue kallikreins: from gene structure to function and clinical applications. Adv. Clin. Chem. 39 (2005), 11–79.
56. Yousef, G.M., Diamandis, E.P., Expanded human tissue kallikrein family–a novel panel of cancer biomarkers. Tumour Biol. 23 (2002), 185–192.
57. Yousef, G.M., Yacoub, G.M., Polymeris, M.E., Popalis, C., Soosaipillai, A., Diamandis, E.P., Kallikrein gene downregulation in breast cancer. Br. J. Cancer 90 (2004), 167–172.
58. Yu, Z., Baserga, R., Chen, L., Wang, C., Lisanti, M.P., Pestell, R.G., microRNA, cell cycle, and human breast cancer. Am. J. Pathol. 176 (2010), 1058–1064.
59. Zhang, B., Pan, X., Cobb, G.P., Anderson, T.A., microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302 (2007), 1–12.
60. Zhou, H., Guo, J.M., Lou, Y.R., Zhang, X.J., Zhong, F.D., Jiang, Z., Cheng, J., Xiao, B.X., Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. (Berl) 88 (2010), 709–717.
61. Zhu, J., Sanborn, J.Z., Benz, S., Szeto, C., Hsu, F., Kuhn, R.M., Karolchink, D., Archie, J., Lenburg, M.E., Esserman, L.J., Kent, W.J., Haussler, D., Wang, T., The UCSC Cancer Genomics Browser. Nat. Methods 6 (2009), 239–240.